Veracyte Inc
Deschisă
SectorSănătate
47.89 1.31
Rezumat
Modificarea prețului
24h
Minim
46.6
Maxim
47.91
Venit | -20M 29M |
|---|---|
Vânzări | -1.6M 139M |
P/E Medie Sector | 45.019 49.052 |
EPS | 0.52 |
Marjă de profit | 20.642 |
Angajați | 755 |
EBITDA | -17M 29M |
Recomandări | Cumpărare |
|---|---|
Prognoză pe 12 luni | +0.51% upside |
Următoarele câștiguri | 5 aug. 2026 |
|---|
Capitalizare de piață | 1.1B 3.8B |
|---|---|
Deschiderea anterioară | 46.58 |
Închiderea anterioară | 47.89 |
Sentimentul știrilor
By Acuity
50%
50%
146 / 342 Clasament în Healthcare
Veracyte Inc Grafic
Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.
Despre Veracyte Inc
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.